If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
bamlanivimab and etesevimab together
bamlanivimab and etesevimab together
700mg/1400mgThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What were the common treatment emergent adverse events with bamlanivimab and etesevimab treatment?
In the BLAZE-1 trial, most treatment-emergent adverse events were mild to moderate in severity; no deaths were reported in the bamlanivimab/ etesevimab treatment arm.
Bamlanivimab and Etesevimab Emergency Use Authorization
Bamlanivimab and etesevimab have not been approved, but have only been authorized for emergency use by Food and Drug Administration (FDA) for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the bamlanivimab and etesevimab under Section 564(b)(1)(C) of the Act, 21 U.S.C. 360bbb-3, unless the authorization is terminated or revoked sooner.1,2
Bamlanivimab and etesevimab are authorized to be administered together in adults and pediatric patients, including neonates, who are at high risk for progression to severe coronavirus disease 2019 (COVID-19), including hospitalization or death for
For information on the authorized use of bamlanivimab and etesevimab together and mandatory requirements under the emergency use authorization (EUA), please review the FDA Letter of Authorization, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients/Caregivers at www.LillyAntibody.com. 1,2
Bamlanivimab and Etesevimab Fact Sheet for Healthcare Providers
Warnings
There are limited clinical data available for bamlanivimab and etesevimab. Serious and unexpected adverse events may occur that have not been previously reported with use of bamlanivimab and etesevimab together.1
Clinical Worsening After Bamlanivimab and Etesevimab Administration
Clinical worsening of COVID-19 after administration of bamlanivimab and etesevimab together has been reported and may include signs or symptoms of
- fever
- hypoxia or increased respiratory difficulty
- arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia)
- fatigue, and
- altered mental status.1
Some of these events required hospitalization. It is not known if these events were related to bamlanivimab and etesevimab use or were due to progression of COVID-19.1
Side Effects
Overall Safety Summary
Clinical Trials Experience
Adults (≥18 Years) and Pediatric Patients (<18 Years and Weighing at Least 40 kg)
The safety of bamlanivimab administered with etesevimab is primarily based on exposure of approximately 1400 ambulatory (nonhospitalized) subjects who received doses of bamlanivimab and etesevimab together, at the recommended dose or higher, in BLAZE-1 and BLAZE-4 (see BLAZE Clinical Trial Designs).1
BLAZE-1 is a phase 2/3, randomized, double-blind, placebo-controlled clinical trial studying bamlanivimab and etesevimab administered together for the treatment of subjects with mild to moderate COVID-19. Thirty-four pediatric patients (ages 12 to <18 years and weighing at least 40 kg) were included in the phase 3 portion of BLAZE-1 (14 received placebo, 14 received the authorized dose or a higher dose for their age, and 6 received a lower dose than authorized for their age). In the phase 3 portion of the trial, enrolled participants had at least one risk factor for the development of severe COVID-19 illness.1
BLAZE-4 is a phase 2, randomized, double-blind, placebo-controlled clinical trial studying bamlanivimab and etesevimab for the treatment of subjects with mild to moderate COVID-19. Subjects ≥65 years old or with a body mass index (BMI) ≥35 were excluded from enrollment.1
In clinical trials, approximately 4000 subjects have received bamlanivimab (either alone or with etesevimab) at doses ranging from 700 to 7000 mg. Bamlanivimab and etesevimab at the authorized doses of 700 mg and 1400 mg have been administered together to approximately 800 subjects in clinical trials.1
The following adverse reactions (i.e., adverse events assessed as causally related) have been observed in those who have received bamlanivimab and etesevimab together at the authorized dose or higher:1
- anaphylaxis (n=1, 0.07%)
- infusion-related reactions (n=16, 1.1%)
In the case of anaphylaxis and serious infusion-related reactions, all infusions were stopped, and treatment was administered. One case required epinephrine. All events resolved.1
The most common treatment-emergent adverse events in the bamlanivimab and etesevimab treatment group in BLAZE-1 and BLAZE-4 included nausea, dizziness, and pruritus. No treatment-emergent adverse events occurred in more than 1% of participants and the rates were comparable in the treatment and placebo groups.1
Pediatric Patients (0 to <18 Years)
The total number of pediatric patients was 125. In addition to the 34 pediatric patients (aged 12 to <18 years and weighing at least 40 kg) enrolled in the phase 3 portion of BLAZE-1, an open-label pediatric addendum to BLAZE-1 enrolled
- 40 patients aged 12 to <18
- 36 patients aged 6 to <12
- 10 patients aged 2 to <6, and
- 5 patients aged 0 to <2.1
All pediatric patients had at least one risk factor for the development of severe COVID-19 illness.1
Pediatric patients weighing 8.6 kg to <40 kg received doses of bamlanivimab and etesevimab that were adjusted for their body weight, to achieve the same exposures as adults and adolescents receiving the authorized dose of 700 mg and 1400 mg, respectively.1
The adverse drug reaction profile in pediatric patients is consistent with the established profile.1
Bamlanivimab and Etesevimab Available Clinical Data
The information presented in the sections below contain data on unauthorized doses of bamlanivimab and etesevimab administered together. Please see the enclosed Fact Sheet for authorized dosing information.
Clinical Trial Design Overview
BLAZE-1 is a phase 2/3 randomized, double-blind, placebo-controlled trial evaluating bamlanivimab alone and together with etesevimab, in non-hospitalized patients with mild to moderate COVID-19.3-5
|
BLAZE-1 Phase 2 (NCT04427501) |
BLAZE-1 Phase 3 (NCT04427501) |
BLAZE-4 Phase 2 (NCT04634409) |
|
Design |
Randomized, double-blind, placebo-controlled trial in non-hospitalized patients with mild to moderate COVID-19 |
Randomized, double-blind, placebo-controlled trial in non-hospitalized patients with mild to moderate COVID-19 and at least 1 risk factorb for developing severe COVID-19 illness |
Randomized, double-blind, placebo-controlled trial in non-hospitalized patients with mild to moderate COVID-19 illness |
|
Primary Endpoint |
Change from baseline to day 11 in SARS-CoV-2 viral load |
Percentage of participants who experience COVID-related hospitalization or death of any cause through day 29 |
Percentage of patients with SARS-CoV-2 viral load greater than 5.27 at day 7 |
|
Treatment arms included in analyses |
Patients randomized to IV infusion of
|
Patients randomized to IV infusion of
|
Patients randomized to IV infusion of
|
Patients 18-64 years old randomized to IV infusion of
|
Abbreviations: BAM = bamlanivimab; BMI = body mass index; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; COVID-19 = coronavirus disease 2019; CVD = cardiovascular disease; ETE = etesevimab; IV = intravenous; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
aBLAZE clinical trials are ongoing studies, outcomes measures, inclusion/exclusion criteria, and eligibility may change throughout the study.
bRisk factors include: ≥ 65 years of age, BMI ≥ 35, CKD, type 1 or type 2 diabetes, immunosuppressive disease, receiving immunosuppressive treatment; ≥ 55 years of age AND have a history of CVD, or hypertension, or COPD or other chronic respiratory disease; 12-17 years of age AND satisfy at least one of the following at the time of screening: BMI ≥85th percentile for their age and gender based on CDC growth charts, sickle cell disease, congenital or acquired heart disease, neurodevelopmental disorders (for example, cerebral palsy), medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation not related to COVID-19), asthma or reactive airway or other chronic respiratory disease, type 1 or type 2 diabetes, immunosuppressive disease, or currently receiving immunosuppressive treatment.
Baseline Demographics and Disease Characteristics
Baseline demographics and disease characteristics were well balanced across treatment groups for each of the studies.1BLAZE Clinical Trials Baseline Demographics and Disease Characteristics provides information by study.
|
BLAZE-1 Phase 2 |
BLAZE-1 Phase 3 |
BLAZE-4 Phase 2 |
Median age, years |
45 |
56 |
39 |
≥ 65 years old |
12% |
31% |
1% |
Female |
55% |
52% |
50% |
White |
89% |
87% |
87% |
Hispanic or Latino |
43% |
29% |
29% |
Black or African American |
6% |
8% |
6% |
High-risk for severe COVID-19 illnessa |
42% |
100% |
8% |
Mild COVID-19 |
78% |
77% |
84% |
Moderate COVID-19 |
22% |
23% |
16% |
Mean duration of symptoms, days |
5 |
4 |
4 |
Mean viral load by CT |
24 |
24 |
25 |
Abbreviations: BMI = body mass index; CKD = chronic kidney disease; COVID-19 = coronavirus disease 2019; CT = cycle threshold.
aHigh risk is defined as patients who meet at least one of the following criteria: BMI ≥35, CKD, diabetes, immunosuppressive disease, receiving immunosuppressive treatment, ≥65 years old, ≥55 years old AND have cardiovascular disease, OR hypertension, OR chronic obstructive pulmonary disease/other chronic respiratory disease. Are 12 – 17 years of age AND have BMI ≥85th percentile for their age and gender based, OR sickle cell disease, OR congenital or acquired heart disease, OR neurodevelopmental disorders, OR a medical-related technological dependence, OR asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.
Bamlanivimab and Etesevimab: Summary of Safety Results
BLAZE-1 Phase 3 Safety Data
Treatment-emergent Adverse Events Reported in ≥ 2 Patients Treated with Bamlanivimab and Etesevimab presents reported TEAEs from an integrated safety analysis set of pooled data from BLAZE-1 and BLAZE-4 (with data through March 12, 2021) and included patients treated with
- bamlanivimab and etesevimab at the authorized doses of 700 mg and 1400 mg or higher (N=1400), or
- placebo (N=985).8
MedDRA System Organ Class Preferred Term |
Placebo (N=985) |
BAM+ETE (N=1400)a |
Gastrointestinal disorders |
20 (2.0) |
32 (2.3) |
Nausea |
6 (0.6) |
12 (0.9) |
Gastroesophageal reflux disease |
1 (0.1) |
5 (0.4) |
Vomiting |
3 (0.3) |
5 (0.4) |
Constipation |
3 (0.3) |
3 (0.2) |
Diarrhea |
3 (0.3) |
3 (0.2) |
Abdominal pain |
2 (0.2) |
2 (0.1) |
Dyspepsia |
1 (0.1) |
2 (0.1) |
Nervous System disorders |
16 (1.6) |
27 (1.9) |
Dizziness |
4 (0.4) |
11 (0.8) |
Headache |
1 (0.1) |
3 (0.2) |
Paresthesia |
4 (0.4) |
3 (0.2) |
Dysgeusia |
1 (0.1) |
2 (0.1) |
Presyncope |
0 |
2 (0.1) |
Sciatica |
0 |
2 (0.1) |
Syncope |
1 (0.1) |
2 (0.1) |
Tremor |
0 |
2 (0.1) |
Infections and Infestations |
22 (2.2) |
25 (1.8) |
Urinary Tract infections |
2 (0.2) |
7 (0.5) |
Pneumonia |
3 (0.3) |
2 (0.1) |
Sinusitis |
2 (0.2) |
2 (0.1) |
Skin and Subcutaneous Tissue disorders |
16 (1.6) |
24 (1.7) |
Rash |
6 (0.6) |
9 (0.6) |
Pruritus |
1 (0.1) |
8 (0.6) |
Urticaria |
1 (0.1) |
4 (0.3) |
General disorders and administration site conditions |
9 (0.9) |
17 (1.2) |
Pyrexia |
0 |
4 (0.3) |
Chest discomfort |
0 |
3 (0.2) |
Extravasation |
0 |
3 (0.2) |
Investigations |
8 (0.8) |
17 (1.2) |
Liver function test increased |
3 (0.3) |
6 (0.4) |
C-reactive protein increased |
1 (0.1) |
3 (0.2) |
Lipase increased |
1 (0.1) |
2 (0.1) |
Respiratory, thoracic and mediastinal disorders |
7 (0.7) |
16 (1.1) |
Rhinalgia |
0 |
3 (0.2) |
Asthma |
1 (0.1) |
2 (0.1) |
Oropharyngeal pain |
0 |
2 (0.1) |
Sinus congestion |
1 (0.1) |
2 (0.1) |
Injury, poisoning and procedural complications |
3 (0.3) |
15 (1.1) |
Fall |
1 (0.1) |
3 (0.2) |
Infusion related reactions |
0 |
3 (0.2) |
Skin laceration |
0 |
2 (0.1) |
Metabolism and nutrition disorders |
8 (0.8) |
14 (1.0) |
Hyperglycemia |
0 |
2 (0.1) |
Hyperlipidemia |
1 (0.1) |
2 (0.1) |
Type 2 diabetes mellitus |
1 (0.1) |
2 (0.1) |
Musculoskeletal and connective tissue disorders |
12 (1.2) |
10 (0.7) |
Arthralgia |
2 (0.2) |
3 (0.2) |
Back pain |
2 (0.2) |
2 (0.1) |
Muscular weakness |
0 |
2 (0.1) |
Vascular disorders |
3 (0.3) |
8 (0.6) |
Hypertension |
2 (0.2) |
4 (0.3) |
Cardiac disorders |
5 (0.5) |
6 (0.4) |
Acute myocardial infarction |
0 |
2 (0.1) |
Blood and lymphatic system disorders |
2 (0.2) |
5 (0.4) |
Anemia |
0 |
3 (0.2) |
Neutropenia |
0 |
2 (0.1) |
Abbreviations: BAM = Bamlanivimab; ETE= Etesevimab; MedDRA = Medical Dictionary for Regulatory Activities
aDoses of bamlanivimab and etesevimab used for this analysis include the authorized doses of 700 mg and 1400 mg or higher (N=1400), or placebo (N=985).
BLAZE-4: Accelerated Infusion Substudy Results
Safety and Tolerability With 15-Minute Infusion
Summary of Adverse Events With 30-Minute and 15-Minute Bamlanivimab and Etesevimab Infusion summarizes the safety of IV administration of undiluted bamlanivimab (20 mL) and undiluted etesevimab (40 mL) added to an empty infusion bag, and infused to patients over 30 or 15 minutes in the BLAZE-4 substudy.
The data from the undiluted treatment arm supported the addition of shorter infusion times added to the Fact Sheet on 09 February 2021.
n (%)a |
BAM 700 mg + ETE 1400 mg |
BAM 700 mg + ETE 1400 mg |
TEAEs |
0 |
3 (10.0) |
Mild |
0 |
2 (6.7) |
Moderate |
0 |
0 |
Severe |
0 |
0 |
Missing data |
0 |
1 (3.3) |
Discontinuation due to AE |
0 |
0 |
SAEs |
0 |
0 |
Death |
0 |
0 |
Abbreviations: % = proportion of patients; AE = adverse event; BAM = bamlanivimab; ETE = etesevimab; SAE = serious adverse event; TEAE = treatment-emergent adverse event.
aNumbers in table represent the number of patients reporting AEs, not number of events.
In the bamlanivimab and etesevimab 15-minute infusion cohort (N = 30), 2 uncoded events were observed. One was defined as an infusion-related reaction and the other defined as shortness of breath/“feeling of infusion” in the chest.8
Enclosed Fact Sheet
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Fact sheet for healthcare providers. Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. US Food and Drug Administration (FDA). 2021.
2United States Food and Drug Administration. Bamlanivimab and etesevimab FDA Emergency Use Authorization letter. Issued December 22, 2021. Accessed December 22, 2021. http://pi.lilly.com/eua/bam-and-ete-eua-fda-authorization-letter.pdf
3Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632-644. http://dx.doi.org/10.1001/jama.2021.0202
4Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis. Published online October 28, 2021. http://dx.doi.org/10.1093/cid/ciab912
5Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate covid-19. N Eng J Med. Published online July 14, 2021. http://dx.doi.org/10.1056/NEJMoa2102685
6A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in participants with mild to moderate COVID-19 illness (BLAZE-1). ClinicalTrials.gov identifier: NCT04427501. Updated September 8, 2021. Accessed September 14, 2021. https://www.clinicaltrials.gov/ct2/show/NCT04427501
7A study of immune system proteins in participants with mild to moderate COVID-19 illness (BLAZE-4). ClinicalTrials.gov identifier: NCT04634409. Updated September 5, 2021. Accessed September 14, 2021. https://clinicaltrials.gov/ct2/show/NCT04634409
8Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
AE = adverse event
ASPR = Assistant Secretary for Preparedness and Response
BAM = bamlanivimab
ETE = etesevimab
COVID-19 = coronavirus disease 2019
EUA = emergency use authorization
FDA = Food and Drug Administration
IV = intravenous
SAE = serious adverse event
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
TEAE = treatment-emergent adverse event
US = United States
Date of Last Review: December 23, 2021